2 results
Approved WMOCompleted
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Approved WMOCompleted
The objective of the study is to evaluate the safety of the extended treatment with oral Cladribine and to determinate the effect on the QTc interval.other objectives:-explore the long term benefit (rate of disease progression as reflected by rate…